Trastuzumab Emtansine

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: HER2-Positive Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

von Minckwitz et al. (N Engl J Med, 2019; PMID 30516102) report different figures for this outcome from the interim analysis: 3-year invasive disease-free survival of 88.3% with T-DM1 and 77.0% with trastuzumab (hazard ratio 0.50).

track record: Partial signal

Also approved (2)
EU
  • Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy...
Product first approved 2013EMA
JP
  • Treatment of unresectable or recurrent HER2- positive breast cancer
Product first approved 2013PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (14)
Breast Cancer
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07578116 · SWOG Cancer Research Network
2027-03-09 – 2033-05-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
What this study did
NCT06316531 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-05-08 – 2028-12 · HER2-positive Breast Cancer
What this study did
NCT07673029 · GeneQuantum Healthcare (Suzhou) Co., Ltd.
2025-01-10 – 2028-01-09 · HER2-positive Breast Cancer
What this study did
NCT05415215 · Hoffmann-La Roche
2022-07-05 – 2025-11-07 · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
What this study did
Phase 2/3 (2)
Breast Cancer
NCT05288777 · University of Virginia
2022-07-11 – 2029-12 · Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
Other / comorbidity
NCT01641939 · Hoffmann-La Roche
2012-09-03 – 2016-04-30 · Gastric Cancer
What this study did
Phase 2 (55)
Breast Cancer
NCT04266249 · ECOG-ACRIN Cancer Research Group
2020-03-13 – 2038-12-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT04733118 · MedSIR
2021-08-05 – 2028-03 · Early Breast Cancer
What this study did
NCT05323955 · Carey Anders, M.D.
2023-03-23 – 2027-11 · Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
What this study did
NCT04680442 · Population Health Research Institute
2021-07-01 – 2026-06-30 · Breast Cancer, Heart Failure
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT04197687 · Academic and Community Cancer Research United
2020-02-20 – 2025-01-15 · Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT03248492 · Daiichi Sankyo
2017-08-25 – 2024-05-06 · Breast Cancer
What this study did
NCT01853748 · Dana-Farber Cancer Institute
2013-05 – 2022-06-15 · Breast Cancer
What this study did
NCT01835236 · Swiss Cancer Institute
2013-03-03 – 2020-05-26 · Metastatic Breast Cancer
What this study did
NCT02725541 · Jenny C. Chang, MD
2016-03 – 2019-05 · Breast Cancer
What this study did
NCT01975142 · Institut Curie
2013-11-07 – 2019-01-21 · Metastatic Breast Cancer, HER2 Negative Primary Tumor
What this study did
NCT02073487 · The Methodist Hospital Research Institute
2014-02 – 2019-01 · Breast Cancer
What this study did
NCT00679211 · Genentech, Inc.
2008-08 – 2011-04 · Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06348134 · University of Chicago
2025-03-18 – 2036-07-01 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
What this study did
NCT06439693 · Dana-Farber Cancer Institute
2024-08-08 – 2033-03-30 · Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT04893109 · Dana-Farber Cancer Institute
2021-06-16 – 2029-05-01 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT02326974 · Dana-Farber Cancer Institute
2015-01 – 2028-01 · HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
What this study did
NCT04398914 · Shanghai Jiao Tong University School of Medicine
2020-05-30 – 2027-12-30 · Breast Cancer Invasive
What this study did
NCT03587740 · Dana-Farber Cancer Institute
2018-08-22 – 2027-08-30 · Breast Cancer
What this study did
NCT04419181 · University of Rochester
2025-08-11 – 2027-06-01 · HER2-positive Breast Cancer
What this study did
NCT06595563 · Jules Bordet Institute
2026-06-30 – 2026-07-23 · HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
What this study did
NCT06125834 · The First Affiliated Hospital with Nanjing Medical University
2023-06-01 – 2026-05-31 · Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine
What this study did
NCT04675827 · Jules Bordet Institute
2022-01-17 – 2024-11-26 · HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
What this study did
NCT01494662 · Dana-Farber Cancer Institute
2012-02 – 2024-04-19 · Breast Cancer
What this study did
NCT03530696 · University of Arizona
2018-12-06 – 2022-12-22 · HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
What this study did
NCT01565200 · Jules Bordet Institute
2012-05 – 2022-12 · HER-2 Positive Breast Cancer
What this study did
NCT03894007 · Renske Altena
2019-05-23 – 2021-06-30 · Early-stage Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT01904903 · Medstar Health Research Institute
2013-10 – 2020-06 · HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
What this study did
NCT03203616 · Jules Bordet Institute
2018-02-23 – 2018-08-27 · Metastatic HER2-positive Breast Cancer With Brain Metastasis
What this study did
Other / comorbidity
NCT05408845 · NRG Oncology
2023-03-03 – 2033-07-31 · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
What this study did
NCT04589845 · Hoffmann-La Roche
2021-01-18 – 2032-09-25 · Solid Tumors
What this study did
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT05673928 · M.D. Anderson Cancer Center
2023-05-16 – 2029-03-01 · Metastatic Solid Tumor, Brain Metastases
What this study did
NCT04620187 · Dana-Farber Cancer Institute
2020-12-24 – 2029-02-01 · Salivary Gland Cancer, HER2 Gene Mutation
What this study did
NCT04931342 · Hoffmann-La Roche
2021-10-07 – 2028-05-30 · Ovarian Cancer
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT07257809 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-10-13 – 2027-09-26 · Thrombocytopenia
What this study did
NCT04439110 · National Cancer Institute (NCI)
2015-08-12 – 2027-03-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT02675829 · Memorial Sloan Kettering Cancer Center
2016-02-16 – 2026-09-04 · Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
What this study did
NCT02314481 · University College, London
2017-05-12 – 2025-11-30 · Non-small Cell Lung Cancer
What this study did
Phase 1/2 (14)
Breast Cancer
NCT05081609 · Ascendis Pharma Oncology Division A/S
2022-01-11 – 2029-08 · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
What this study did
NCT06324357 · Boehringer Ingelheim
2024-06-28 – 2029-01-08 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
What this study did
NCT02658084 · University of Miami
2017-04-12 – 2018-10-11 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02318901 · Western Regional Medical Center
2014-10 – 2018-08 · Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
What this study did
NCT00934856 · Hoffmann-La Roche
2009-07 – 2013-10 · Breast Cancer
What this study did
NCT00951665 · Genentech, Inc.
2009-08 – 2013-06 · Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT05593094 · Hoffmann-La Roche
2020-09-03 – 2027-08-31 · Advanced Solid Tumors, HER2-positive Breast Cancer
What this study did
NCT03190967 · National Cancer Institute (NCI)
2018-04-18 – 2023-06-13 · Breast Cancer, Brain Metastasis, Brain Cancer
What this study did
NCT03709082 · University of Kansas Medical Center
2018-10-15 – 2021-02-03 · HER2-positive Breast Cancer, Breast Cancer Metastatic
What this study did
Other / comorbidity
NCT04486352 · Alliance Foundation Trials, LLC.
2021-10-20 – 2027-10 · Endometrial Cancer
What this study did
Phase 1 (20)
Breast Cancer
NCT05650879 · Enliven Therapeutics
2023-03-20 – 2026-07 · HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03032107 · Dana-Farber Cancer Institute
2017-02-17 – 2024-12-05 · Breast Cancer
What this study did
NCT02390427 · Nancy Lin, MD
2015-04-20 – 2024-07 · Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT04296942 · National Cancer Institute (NCI)
2021-05-04 – 2021-10-22 · Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01976169 · University of Texas Southwestern Medical Center
2014-01-24 – 2021-05-19 · Advanced Breast Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01983501 · Seagen Inc.
2014-02-28 – 2020-09-03 · HER2 Positive Breast Cancers
What this study did
NCT02605915 · Hoffmann-La Roche
2015-12-31 – 2019-11-13 · HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
What this study did
NCT03153163 · Hoffmann-La Roche
2017-06-20 – 2018-09-27 · Breast Neoplasms
What this study did
NCT01816035 · University of Washington
2014-06 – 2017-04 · HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01513083 · Hoffmann-La Roche
2012-02 – 2014-09 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT04509596 · Dizal Pharmaceuticals
2020-09-21 – 2022-07-07 · Breast Cancer Metastatic
What this study did
NCT03364348 · George W. Sledge Jr.
2017-10-30 – 2022-02-14 · HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT04042051 · Cancer Trials Ireland
2019-11-12 – 2020-11-02 · HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Cancer
What this study did
NCT03429101 · Spectrum Pharmaceuticals, Inc
2018-07-13 – 2019-04-17 · Breast Cancer
What this study did
NCT02073916 · Jenny C. Chang, MD
2013-10 – 2018-12 · Metastatic Breast Cancer
What this study did
NCT02038010 · Northwestern University
2014-05-21 – 2017-05-20 · HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02135159 · Institut du Cancer de Montpellier - Val d'Aurelle
2014-02 – 2017-03 · HER2-positive Breast Cancer
What this study did
Phase 4 (1)
HER2-Positive Breast Cancer
NCT02658734 · Hoffmann-La Roche
2016-11-01 – 2019-12-14 · HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
What this study did
Early phase / not applicable (4)
Breast Cancer
NCT06299852 · N.N. Petrov National Medical Research Center of Oncology
2022-07-01 – 2025-09-01 · HER2-positive Metastatic Breast Cancer, Oligometastatic Disease
What this study did
NCT05560308 · Tianjin Medical University Cancer Institute and Hospital
2022-09-30 – 2025-08-23 · HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
What this study did
HER2-Positive Breast Cancer
NCT07198672 · Zhenzhen Liu
2025-10-31 – 2028-10-31 · HER2-positive Breast Cancer
What this study did
NCT02226276 · City of Hope Medical Center
2015-02-25 – 2027-09-07 · Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer
What this study did
Used as active comparator (11)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Breast Cancer
NCT06126640 · Jiangsu HengRui Medicine Co., Ltd.
2023-11-20 – 2032-04 · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
What this study did
NCT07008976 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-07-07 – 2028-12 · Metastatic Breast Cancer
What this study did
NCT04622319 · Daiichi Sankyo
2020-12-04 – 2028-06-20 · HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
What this study did
NCT05755048 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023-03-28 – 2026-01-31 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06830889 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-03 – 2031-12 · HER2-positive Breast Cancer
What this study did
NCT06846437 · Shanghai JMT-Bio Inc.
2025-02-18 – 2028-12-31 · Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
What this study did
NCT06265428 · DualityBio Inc.
2024-01-29 – 2028-12 · HER2-positive Breast Cancer
What this study did
NCT06968585 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023-07-18 – 2028-03-31 · HER2-positive Breast Cancer
What this study did
NCT06313086 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-03-13 – 2028-02 · HER2-positive Breast Cancer
What this study did
Phase 2/3 (1)
Breast Cancer
NCT04924699 · Shanghai Miracogen Inc.
2021-06-30 – 2023-10 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Breast Cancer
HER2-Positive Breast Cancer
NCT04457596 · Alliance for Clinical Trials in Oncology
2021-03-02 – 2035-05-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
What this study did
NCT03975647 · Seagen, a wholly owned subsidiary of Pfizer
2019-10-02 – 2029-03-10 · HER2-positive Breast Cancer
What this study did
Phase 2 (3)
Breast Cancer
NCT04351230 · Academic and Community Cancer Research United
2020-11-11 – 2022-02-16 · Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
HER2-Positive Breast Cancer
NCT04158947 · xuexin he
2020-05-10 – 2024-03-31 · HER2-positive Breast Cancer, Brain Metastases
What this study did

Competitive landscape

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Emtansine: this drugApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab Emtansine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT05323955 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-01-09 · NCT07673029 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-03 · NCT04733118 · CT.gov ↗
What to watch
Phase 2Metastatic Solid Tumor, Brain MetastasesRecruiting
Est. primary completion 2027-03-01 · NCT05673928 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Neoplasm MetastasisActive not recruiting
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07-15 · NCT04301375 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-08 · NCT05081609 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT04266249 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT07198672 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (5)
February 2028 (2)
Phase 2Salivary Gland Cancer, HER2 Gene MutationRecruiting
Est. primary completion 2028-02-01 · NCT04620187 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-31 · NCT05408845 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT04893109 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-12 · NCT05288777 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2032 (2)
May 2032 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2032-05-31 · NCT07578116 · CT.gov ↗
What to watch
September 2032 (1)
Phase 2Solid TumorsActive not recruiting
Est. primary completion 2032-09-25 · NCT04589845 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch

See the full readout calendar ↗